When EF>60 percent, the SGLT2 inhibitor ertugliflozin is unable to prevent HF hospitalization, according to VERTIS CV analyses.

Published Date: 27 Oct 2023

USA: Post-hoc analyses of the VERTIS CV trial failed to show the ability of SGLT2 inhibitor ertugliflozin (Steglatro) to reduce hospitalization for.

Read Full News

Latest News

Lentigo Maligna Rarely Progresses Despite Rising Incidence

Despite rising cases in recent years, lentigo maligna shows minimal progression to melanoma, and patients with this condition are more likely to die due to other factors, a retrospective study finds.

Baxdrostat Approval May Open Doors for HTN Therapy

The FDA’s recent approval of baxdrostat may usher in new possibilities for treatment for uncontrolled hypertension.

Eating for One: The Future of Personalized Nutrition

Nutrition science is closing in on truly personalized dietary advice. The bigger challenge? Making sure it does not only land on wealthy plates.

When the Defibrillator Stays in Its Box

After teenage footballer Adam Ankers died in cardiac arrest while a defibrillator sat unused on the pitch, 13 organisations now have until June to respond to a coroner's report.

Is Hypertension Undertreated in Pediatrics?

Long-term implications may be underestimated, and new data show relatively low medication use.

Prior Auth Rules Vary Widely Across Insurers, Study Finds

A new study finds that prior authorization requirements vary widely across major insurers and suggests large language models could help streamline how authorization rules are interpreted and processed.

Todays Updates

EMA Backs Breast Cancer SERD After FDA No Vote

The recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.

Datopotamab Deruxtecan Earns New Breast Cancer Indication

The antibody drug conjugate was approved by the FDA for certain patients with triple-negative breast cancer.

Todays Updates

EMA Backs Breast Cancer SERD After FDA No Vote

The recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.

Datopotamab Deruxtecan Earns New Breast Cancer Indication

The antibody drug conjugate was approved by the FDA for certain patients with triple-negative breast cancer.

Latest News

Despite rising cases in recent years, lentigo maligna shows minimal progression to melanoma, and patients with this condition are more likely to die due to other factors, a retrospective study finds.

The FDA’s recent approval of baxdrostat may usher in new possibilities for treatment for uncontrolled hypertension.

Nutrition science is closing in on truly personalized dietary advice. The bigger challenge? Making sure it does not only land on wealthy plates.

After teenage footballer Adam Ankers died in cardiac arrest while a defibrillator sat unused on the pitch, 13 organisations now have until June to respond to a coroner's report.

Long-term implications may be underestimated, and new data show relatively low medication use.

A new study finds that prior authorization requirements vary widely across major insurers and suggests large language models could help streamline how authorization rules are interpreted and processed.

News All Time

How Lifeline Brought the AMR Crisis to the London Stage

Real doctors joined the London cast of Lifeline the Musical to bring the growing threat of antimicrobial resistance to wider audiences.

Cardiorenal Benefits of GLP-1s Found in Type 1 Diabetes

A large database study shows lower risk for major adverse cardiovascular events and end-stage kidney disease, with no increase in adverse events.

Germany Flags Safety Risks in ‘Vitamin Drip’ Trend

BfArM warns ‘vitamin drips’ can cause hypervitaminosis, electrolyte imbalance, allergic reactions up to anaphylaxis, fluid overload, and IV complications such as air embolism.

Arterial Widening, Not Blockage, Tied to Common Stroke

Arterial widening, not vessel blockage, is strongly associated with lacunar stroke, a finding that could explain why conventional antiplatelet therapies offer limited benefit.

Single-Pill Hypertension Therapy Remains Underutilized

Single-pill combination therapy remains underused as the initial treatment for adults newly diagnosed with hypertension, despite repeated guideline recommendations.

Maternal Diabetes in Pregnancy Tied to CVD Risk in Children

Maternal diabetes during pregnancy is associated with an increased risk for cardiovascular disease in offspring, and part of this association is explained by birth complications.

Polycystic Ovary Syndrome Demands Multidisciplinary Approach

Along with endocrinologists, ob/gyns, mental health professionals, and nutritionists, dermatologists play a key role in addressing polycystic ovary syndrome, experts say.

Time in Target Range Metric May Aid in CKD Management

The urine albumin/creatinine ratio time in target range predicts cardiovascular outcomes in people with and without chronic kidney disease.

SSRI vs NDRI: Which Is Better for Post-Stroke Depression?

Bupropion is linked to lower suicidal ideation risk but higher odds of demoralization and apathy vs fluoxetine in post-stroke depression, new research shows.

TADV Saves Limbs in No-Option CLTI Patients

More than 80% of no-option chronic limb-threatening ischemia patients avoided amputation for 6 months after the procedure while enjoying improved wound healing and reduced pain.

Underground Hospitals: Is Combat Medicine Entering a New Era?

Ukrainian clinicians increasingly rely on protected underground facilities as drone threats complicate evacuation and strain traditional battlefield treatment models.

France Focuses on Drugs That Raise Fall Risk in Older Adults

Long-term benzodiazepines and anticholinergics drive falls in seniors; prioritize nonpharmacologic care and deprescribing to cut injuries and hospitalizations.

Uraemic Marker Predicts Mortality After Kidney Transplant

Plasma levels of symmetric dimethylarginine are independently associated with an increased risk for mortality in adult kidney transplant recipients, a prospective study finds.

GLP-1 Drugs Tied to Cardiovascular Benefits in T1D

Adults with T1D who receive GLP-1-based therapy may have a lower risk for adverse cardiovascular outcomes and no significant increase in diabetic ketoacidosis compared with those who do not.

Transient Neurologic Symptoms: What Clinicians Miss

Speakers warn that transient neurologic events may conceal high-risk vascular disease, seizures, or amnestic syndromes requiring rapid evaluation.

SGLT2 Inhibitors Show Similar Cardiorenal Benefits

Empagliflozin and dapagliflozin show similar effectiveness in preventing cardiorenal outcomes among patients with type 2 diabetes without prior cardiovascular or renal disease.

Recommended News For You

November 2023, Medical Bulletin 04/.

Data-driven risk stratification guides childhood brain tumor treatment, reducing side effects

FDA Bans Red Dye No. 3 From Foods, Ingested Drugs

Prostate cancer mortality is significantly reduced when docetaxel is used.

Hair Growth After Cancer; 'Global' Early-Onset CRC; Retifanlimab Boosts OS in NSCLC

Gene therapy for glioblastoma is effectively created by researchers.

New imaging solution could help improve survival for patients with recurring prostate cancer

Recommended Articles For You

Unlocking the Key to Treating Lymphoma: New Innovations in Cancer Research 

Ultimate Guide to Oncology Services in the USA 

Biomimetic Nanovesicles for Breast Cancer: Targeting Senescence to Overcome Chemoresistance 

Seeing the Unseen: The Benefits of Early Stage Breast Cancer Ultrasound 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Year in Review: Chronic Lymphocytic Leukemia

2.

According to a study, white Americans are overdiagnosing melanoma at an alarming rate.

3.

Approval in Endometrial Cancer Expanded; Masks at Cancer Centers; NPR Reporter Dies

4.

The First Gene Therapy Provides a Durable Response for Non-Muscle-Invasive Bladder Cancer.

5.

Canine Cancer Vaccine: A Potential Resurrection? U.S. KK. Snubs Enertu.

1.

What Is Carboxyhemoglobin And How Can It Affect Your Health?

2.

Lu-177 Vipivotide in Prostate Cancer: A Breakthrough in Radioligand Therapy

3.

Unraveling the Mysteries of Coagulopathy: A Comprehensive Definition

4.

Machine Learning in Genomic Analysis for Early Lung Cancer Detection: Key Advances and Insights

5.

A New Perspective on Spherocytosis: Uncovering Innovative Treatments

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II

2.

Navigating the Complexities of Ph Negative ALL - Part XIII

3.

Updates on the First Line Management of ALK+ NSCLC

4.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part IV

5.

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot